EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

New benzimidazole‐oxadiazole derivatives as potent VEGFR‐2 inhibitors: Synthesis, anticancer evaluation, and docking study

Ulviye Acar Çevik iD, Ismail Celik iD, Şennur Görgülü iD, Zeynep Deniz Şahin Inan, Hayrani Eren Bostancı, Yusuf Özkay, Zafer Asım Kaplacıklı iD

Drug Development Research · 2024

DOI: 10.1002/ddr.22218 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Drug Development Research, 2024. Verfasst von Ulviye Acar Çevik und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Anadolu University, Eskişehir, Turkey. Hauptthemen laut MEDLINE: Vascular Endothelial Growth Factor Receptor-2, Molecular Docking Simulation, Oxadiazoles, Antineoplastic Agents. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Anadolu Üniversitesi.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

We report herein, the design and synthesis of benzimidazole‐oxadiazole derivatives as new inhibitors for vascular endothelial growth factor receptor‐2 (VEGFR‐2). The designed members were assessed for their in vitro anticancer activity against three cancer cell lines and two normal cell lines; A549, MCF‐7, PANC‐1, hTERT‐HPNE and CCD‐19Lu. Compounds 4c and 4d were found to be the most effective compounds against three cancer cell lines. Compounds 4c and 4d were then tested for their in vitro VEGFR‐2 inhibitory activity, safety profiles, and selectivity indices using the normal hTERT‐HPNE and CCD‐19Lu cell lines. It was determined that compound 4c was the most effective and safe member of the produced chemical family. Vascular endothelial growth factor A (VEGFA) immunolocalizations of compounds 4c and 4d were evaluated relative to control by VEGFA immunofluorescence staining. Compounds 4c and 4d inhibited VEGFR‐2 enzyme with half‐maximal inhibitory concentration values of 0.475 ± 0.021 and 0.618 ± 0.028 µM, respectively. Molecular docking of the target compounds was carried out in the active site of VEGFR‐2 (Protein Data Bank: 4ASD).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Vascular Endothelial Growth Factor Receptor-2Molecular Docking SimulationOxadiazolesAntineoplastic AgentsBenzimidazolesHumansProtein Kinase InhibitorsCell Line, TumorStructure-Activity RelationshipDrug Screening Assays, AntitumorVascular Endothelial Growth Factor ACell Proliferation

Stichwörter der Autor:innen

MTTVEGFR‐2benzimidazolecytotoxicitymolecular dockingoxadiazole

Substanzen

Vascular Endothelial Growth Factor Receptor-2OxadiazolesAntineoplastic AgentsBenzimidazolesKDR protein, humanProtein Kinase InhibitorsVascular Endothelial Growth Factor A

Autor:innen und Institutionen

  • Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Anadolu University, Eskişehir, Turkey.
  • Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Erciyes University, Kayseri, Turkey.
  • Medicinal Plant, Drug and Scientific Research and Application Center (AUBIBAM), Eskişehir, Turkey.
  • Department of Histology and Embryology, Sivas Cumhuriyet University, Sivas, Turkey.
  • Department of Biochemistry, Faculty of Pharmacy, Cumhuriyet University, Sivas, Turkey.

ORCID-Profile: Ulviye Acar Çevik, Ismail Celik, Şennur Görgülü, Zafer Asım Kaplacıklı

Förderung

  • Anadolu Üniversitesi

Zitieren

APA

Acar Çevik, U., Celik, I., Görgülü, Ş., Şahin Inan, Z. D., Bostancı, H. E., Özkay, Y., & Kaplacıklı, Z. A. (2024). New benzimidazole‐oxadiazole derivatives as potent VEGFR‐2 inhibitors: Synthesis, anticancer evaluation, and docking study. Drug Development Research. https://doi.org/10.1002/ddr.22218

Vancouver

Acar Çevik U, Celik I, Görgülü Ş, Şahin Inan ZD, Bostancı HE, Özkay Y, et al. New benzimidazole‐oxadiazole derivatives as potent VEGFR‐2 inhibitors: Synthesis, anticancer evaluation, and docking study. Drug Development Research. 2024. doi:10.1002/ddr.22218

BibTeX
@article{Acarevik2024,
  author = {Acar Çevik, Ulviye and Celik, Ismail and Görgülü, Şennur and Şahin Inan, Zeynep Deniz and Bostancı, Hayrani Eren and Özkay, Yusuf and Kaplacıklı, Zafer Asım},
  title = {New benzimidazole‐oxadiazole derivatives as potent VEGFR‐2 inhibitors: Synthesis, anticancer evaluation, and docking study},
  journal = {Drug Development Research},
  year = {2024},
  doi = {10.1002/ddr.22218}
}
Kostenlos starten →